Interfering with pH regulation in tumours as a therapeutic strategy

By D. Neri, Claudiu T. Supuran. Nature reviews. Drug discovery, 2011

1,497 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

ANTIANGIOGENESIS STRATEGIES REVISITED: FROM STARVING TUMORS TO ALLEVIATING HYPOXIA (2014, neutral): “…and Simon, 2012); resistance to radiotherapy, chemotherapy, and immunotherapy (e.g., fewer oxygen radicals and cell cycle arrest) (Huang et al., 2013; Neri and Supuran, 2011; Wilson and Hay, 2011); tumor growth and genomic instability and expression of growth factors (e.g., IGF1 and TGF-a),…”
The Smart Drug Delivery System and Its Clinical Potential (2016, background): “Many researches have focused on the design rationale of pH environment activated nanoparticles for smart DDSs [21, 26, 27, 80-82].”
The Antibody-Based Delivery of Interleukin-12 to the Tumor Neovasculature Eradicates Murine Models of Cancer in Combination with Paclitaxel (2012, neutral): “using, inmost cases, antibodies specific to splice isoforms of fibronectin or of tenascin-C (1, 5).”
Insight into nanoparticle cellular uptake and intracellular targeting (2014, neutral): “The NHE1 inhibitors are being employed as selective tumor drugs [34, 151, 152].”
Combination therapy in combating cancer (2017, background): “As discussed earlier, carbonic anhydrase inhibitors (CAIs) have multiple treatment purposes, such as in glaucoma therapy, epilepsy, anti-infective treatment, and also certain types of cancers [66, 77, 78].”